The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and dia...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2017-11, Vol.95, p.469-476
Main Authors: Fernandes, Renata Salgado, de Aguiar Ferreira, Carolina, Soares, Daniel Cristian Ferreira, Maffione, Anna Margherita, Townsend, Danyelle M., Rubello, Domenico, de Barros, André Luís Branco
Format: Article
Language:English
Subjects:
Animals
Anti-tumor efficacy
Antineoplastic Agents - therapeutic use
Diagnostic Imaging
Humans
Neoplasms - diagnostic imaging
Neoplasms - drug therapy
Radiolabeled probes
Radiopharmaceuticals - chemistry
Therapeutic monitoring
Therapy response
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2017.08.079